Achieving vaccine equity: challenges & opportunities of multi-modality manufacturing

Next-generation vaccine platforms comprise different modalities, including viral vectors (e.g., AAV, pDNA, and mRNA.) These vaccine platforms have become popular among the biopharmaceutical industry but also entail several manufacturing challenges. This Expert Insight outlines the manufacturing processes of these vaccine platforms, the difficulties faced by manufacturers who choose to implement multiple modalities, factors to consider when working with smaller batches, and the benefits of implementing digitization. Streamlining the manufacturing process with cost in mind may increase the adoption of these new vaccine technologies globally, including in developing countries.

Please enter your email to access content Read now